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Abstract
Background: The aim of the study was to determine, whether electrocardiogram (ECG) 
screening could reduce the risk of sudden cardiac death in patients with hearing loss through 
the early diagnosis of Jervell and Lange-Nielsen syndrome and the introduction of the therapy.
Methods: One thousand and eighty patients with hearing loss (aged 21.8 ± 19.9 years) un-
derwent ECG. Additionally, all subjects were asked to complete a 3-question survey. Those who 
met, at least, one of the high-risk criteria underwent further cardiac assessment and genetic 
testing.
Results: QTc assessment was possible in 1,027 patients. Mean QTc measured 422.8 ± 23.7 ms  
in 313 women, 414.9 ± 27.7 ms in 273 men and 421.1 ± 21.5 ms in 441 children (individu-
als younger than 14 years). Abnormal QTc was found in 13 (4.1%) women, 20 (7.3%) men, 
and 72 (16.3%) children. In the studied group, no recessive mutation of KNCQ1 or KCNE1 
was found. In 6 patients, other mutations were found: in KCNQ1 (n = 1), in KCNH2  
(n = 3) and in SCN5A (n = 1), which were pathogenic for long-QT-syndromes (LQTS), and  
2 mutations of unknown clinical significance in SCN5A. Overall, out of these 6 patients LQTS 
was diagnosed in 3 asymptomatic patients, but with abnormal QTc and in 2 patients with 
normal QTc, but who were previously treated for epilepsy.
Conclusions: Jervell and Lange-Nielsen syndrome is a very rare condition even in a popula-
tion with hearing loss. In this population, the prevalence of prolonged QT interval is increased 
over the general population. Further investigations are necessary. (Cardiol J 2016; 23, 1: 34–41)
Key words: long-QT syndrome, hearing loss, Jervell and Lange-Nielsen  
syndrome, electrocardiogram
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Introduction
The Jervell Lange-Nielsen syndrome (JL-N) 
(a long-QT-syndrome variant associated with the 
deafness) is a rare and severe type of long-QT-syn-
drome (LQTS). It is an inherited autosomal reces-
sive disorder. The disease is caused by the mutations 
in at least one of the two genes: KCNQ1 or KCNE1. 
These genes encode alpha and beta subunits of the 
potassium channel which mediates IKs current [1] 
and their mutations result in an abnormal function of 
the potassium channel and subsequent prolongation 
of the ventricular repolarization phase. The latter 
predisposes to ventricular tachyarrhythmias such 
as ‘torsade de pointes’ or ventricular fibrillation and 
can lead to fainting, syncope or sudden cardiac death. 
The JL-N syndrome is characterized by high mor-
tality in young age (27% of sudden deaths occur by 
the age of 8.5 years). Sudden cardiac death is often 
the first manifestation of the heart being involved in 
the disease process [1]. Electrocardiography (ECG) 
changes, like an extremely abnormal repolarization 
pattern and a very long QTc interval (557 ± 65 ms), 
typically occur very early in life [1]. The presence 
of such changes in a person with the hearing loss 
immediately raises a suspicion of a JL-N syndrome 
and allows implementation of prophylactic life-
saving treatment. Besides the British Association 
of Paediatricians in Audiology (BAPA) and British 
Association of Audiological Physicians (BAAP) to 
screen every patient with congenital hearing loss 
with ECG, other organizations do not recommend 
routine ECG in this group of patients [2]. How-
ever, guidelines clearly do emphasize ECG utility 
in patients with a history of loss of consciousness, 
arrhythmia or family history of sudden death [3].
The aim of this study was to determine wheth-
er ECG screening could reduce the risk of sudden 
cardiac death in patients with hearing loss through 
an early diagnosis of JL-N syndrome and introduc-
tion of the therapy. ECG studies were performed 
in patients with hearing loss to identify subjects 
with long QTc interval (LQT). Subsequently, LQT 
(including JL-N) syndromes were confirmed by 
cardiac and genetic testing. Theoretically, an early 
identification of JL-N syndrome would allow an in-
troduction of appropriate treatment and prevention 
of serious arrhythmias or sudden cardiac death.
Methods
Studied population
In the prospective manner, 1,080 patients were 
enrolled from two outpatient audiology clinics and 
three schools for children with hearing loss. Stud-
ied population consisted of 562 (52%) females and 
518 (48%) males with confirmed hearing loss, aged 
21.8 ± 19.9 years (0.16–84 years). It also included 
454 (42%) children aged less than 14 years. All 
underwent a 12-lead ECG.
For the purpose of the study, we used the 
following criteria for hearing loss: sensorineural 
hearing loss of 30 dB HL or more (calculated as 
average hearing thresholds for frequencies rel-
evant to speech understanding 500 Hz, 1000 Hz, 
2000 Hz and 4000 Hz). Of all studied, 301 patients 
had cochlear implants. 707 patients were divided 
into six groups according to the type and the degree 
of hearing loss per audiological data. These were 
only available in patients from outpatient clinics — 
we had no access to the precise audiological data 
of children examined at schools. The majority of 
patients (n = 525) had congenital sensorineural 
bilateral hearing loss and were divided into four 
groups: 1) patients with bilateral significant or 
profound sensorineural hearing loss (defined as the 
average hearing threshold of 70 dB HL or more at 
frequencies: 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz, 
and not meeting criteria for the forth group) 
(n = 426), 2) medium-grade sensorineural hear-
ing loss (defined as the average hearing threshold 
between 69 dB HL and 50 dB HL at frequencies: 
500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz, and not 
meeting criteria for the fourth group) (n = 55), 
3) low-grade sensorineural hearing loss (defined as 
the average hearing threshold between 49 dB HL 
and 30 dB at frequencies: 500 Hz, 1000 Hz, 2000 Hz, 
and 4000 Hz, and not meeting criteria for the 
fourth group) (n = 17), 4) bilateral partial deafness 
(patients with low-frequency residual hearing, 
defined as the average hearing threshold of 60 dB 
HL at frequencies: 125 Hz, 250 Hz, and 500 Hz) 
(n = 27). Additionally, there were 182 patients with 
hearing loss of unknown cause: group 5) patients 
with a history of an episode of idiopathic sudden 
deafness (n = 19), 6) with acquired varying degrees 
of bilateral sensorineural hearing loss of unknown 
etiology (n = 163).
Electrocardiographic testing
All 1,080 patients underwent a 12-lead ECG. 
ECG recordings (recorded with a sampling frequen-
cy of 1000 Hz) were performed in the outpatient 
Audiology Departments and schools and sent for 
the evaluation to the cardiology center using the 
Cardiology Information Management System Sen-
tinel Reynolds Medical. ECG evaluation was done 
by a single observer (cardiologist). QT interval 
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measurements were performed electronically on 
the 5× enlarged views of evolutions with an accu-
racy of 1 ms. The QT interval was measured in the 
same cardiac cycle in at least three leads (usually 
in leads: II, V2, and V5). To correct the QT interval 
for heart rates between 50 and 120 bpm Bazett’s 
formula was used. For faster and slower heart 
rates Hodges formula was used. Heart rate was 
calculated based on the RR interval measurement. 
We selected the RR interval preceding the QRS 
complex — the one for which QT interval was being 
measured. Patients with QRS complexes of 120 ms 
or more were excluded from the average QTc calcu-
lation. Fifty-three recordings were excluded from 
the calculation of the mean QTc due to the pres-
ence of any of the following: pre-excitation pattern, 
intraventricular conduction block, QRS complexes 
measuring 120 ms or more, ventricular pacing or 
artifacts, as all these could prevent reliable QTc de-
termination. Based on differences in physiology of 
cardiac conduction and inherent varying reference 
values for QTc between children and adults, males 
and females, study population was divided into 
3 categories: 1) 454 (42%) children younger than 
14 years (232 were girls), 2) 330 (30.5%) females 
14 or more years old and 3) 296 (27.5%) males 
14 or more years old [4]. All subjects were asked 
to complete a 3-question survey on the presence 
of 1) personal history of loss of consciousness or 
fainting associated with palpitations, 2) personal 
history of epilepsy, 3) family history of the sudden 
death or loss of consciousness. Based on the num-
ber of positive answers, and calculated QTc length 
some subjects were rated as “high-risk”. Specific 
criteria for such rating were: 1) positive response 
to all 3 questions in the survey, 2) any 2 positive 
responses and QTc longer than 440 ms, 3) QTc 
longer than 455 ms. Patients rated as “high-risk” 
attended further cardiac evaluation including ECG 
exercise testing, 24-h Holter-ECG, and genetic 
testing. During exercise testing the occurrence 
of ventricular arrhythmias and QTc length (before 
exercise, at peak exercise and after exercise test) 
were evaluated. Holter results were assessed for 
the presence of ventricular arrhythmias. Automatic 
measurement and calculation of the QT and QTc 
intervals was performed wherever possible.
Genotyping
DNA was isolated from peripheral blood leu-
kocytes using the phenol method. Four genes 
were sequenced: KCNQ1, KCNH2, SCN5A, and 
KCNE1. We used the Next-Generation Sequencing 
and traditional Sanger method. Analysis was per-
formed on the Amplicon Variant Analysis software. 
Primers used in genotyping were designed in the 
Laboratory of Molecular Biology of the Institute 
of Cardiology and they are available upon request. 
The presence of the pathogenic mutations was 
confirmed with Sanger method.
Consenting and approval
The Bioethics Committee of the Institute 
of Cardiology approved the project. All enrolled 
patients (or when applicable their legal guard-
ians) have given their written informed consent 
to participate. Written informed consent has been 
additionally received from patients rated as high-
risk who agreed to participate in further steps of 
the study.
Results
Characteristics of the study population
Electrocardiogram was analyzed in 1,080 
patients (53 recordings were excluded from the 
calculation of the mean QTc due to the presence 
of any of the following: pre-excitation pattern, in-
traventricular conduction block, QRS complexes 
measuring 120 ms or more, ventricular pacing or 
artifacts). The survey was completed by 887 (82%) 
patients; 107 out of 887 subjects reported a loss 
of consciousness or palpitations associated with 
fainting, 40 subjects were diagnosed with epilepsy 
and 46 people had a family history of sudden death 
or loss of consciousness. Altogether 96 (8.9%) pa-
tients met criteria for the high risk: 6 patients met 
the 1st criterion, 3 patients met the 2nd criterion, 
and 88 patients met the 3rd criterion.
Electrocardiogram
The results of the QTc calculations, with an 
accuracy of 1 ms, are demonstrated in Table 1.
In females 14 years old and older mean QTc was 
422.8 ± 23.7 ms, ranging from 352 ms to 495 ms. 
Out of these females, 13 (4.1%) had QTc exceeding 
the reference value. Their mean QTc was 472.2 ± 
± 10.1 ms. In males 14 years old and older, mean QTc 
was 414.9 ± 27.7 ms, ranging from 343 ms to 517 ms. 
Out of these males, 20 (7.3%) had prolonged QTc 
with a mean value of 467.8 ± 16.4 ms and 1 male 
had QTc longer than 500 ms. Mean QTc interval 
in children (individuals younger than 14 years 
old) was 421.1 ± 21.5 ms, ranging from 366 ms to 
483 ms. QTc exceeding 440 ms was observed in 
72 (16.3%) children. However, the QTc prolonga-
tion did not exceed 500 ms. Therefore, nobody 
was diagnosed with LQTS meeting solely a “QTc 
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length” criterion. In the entire study population, 
no statistically significant correlation between 
hearing loss pattern and the presence of QTc 
prolongation was found (p = 0.0596). From the 
96 patients who fulfilled the criteria of the high-risk 
group, 62 attended follow-up appointments. The 
automatic calculation of the QT and QTc intervals 
throughout the 24 h period was performed in 
35 subjects with Holter monitoring. In 7 patients, 
periodic QTc prolongation of up to 643 ms was 
found. It was present in less than 1% of monitor-
ing time. Two other patients had an abnormal QTc 
response to exercise. However, none of these 
patients had syncope or arrhythmia. Before geno-
typing was completed, LQTS diagnosis was made 
in 3 asymptomatic patients based on the history, 
another ECG, exercise testing and Holter monitor-
ing (HRS/EHRA/APHRS Expert Consensus 2013 
criteria were used) (Table 2) [5].
Other ECG abnormalities
We analyzed the incidence of other ECG ab-
normalities in the study population. We found atrial 
rhythm in 15 patients, wandering atrial pacemaker in 
2 patients, sinus bradycardia in 125 patients, atrial 
fibrillation in 3 patients, first-degree atrioventricu-
lar block in 19 patients, signs of pre-excitation in 
2 patients, right bundle branch block (complete or in-
complete) in 39 patients, left anterior fascicular block 
in 12 patients, complete left bundle branch block in 
2 patients, nonspecific intraventricular conduction dis-
turbances in 35 patients, signs of left atrial hypertrophy 
in 24 patients, signs of myocardial ischemia in 5 pa- 
tients, and signs of myocardial necrosis in 4 patients.
Table 1. The results of QTc measurements by enlarged evolution method with an accuracy of 1 ms.
Minimal  
QTc  
[ms]
Maximal 
QTc  
[ms]
Mean  
QTc ± SD  
[ms]
Number of  
subjects with QTc 
above the normal 
range (% of the 
group)*
Mean QTc ± SD in 
subjects with QTc 
above the normal 
range [ms]*
Female ≥ 14 years of age (n = 313) 352 495 422.8 ± 23.7 13 (4.1%) 472.2 ± 10.1
Male ≥ 14 years of age (n = 273) 343 517** 414.9 ± 27.7 20 (7.3%) 467.8 ± 16.4
Children < 14 years of age (n = 441) 366 483 421.1 ± 21.5 72 (16.3%) 454.0 ± 11.8
*Normal QTc range: ≤ 460 ms in women, ≤ 450 ms in men, ≤ 440 ms in children under 14 years of age; **QTc > 500 ms was found in one 
male; SD — standard deviation
Table 2. The results of QTc in other cardiac investigations in high-risk patients that attended their  
appointment.
QT ± SD [ms] QTc ± SD [ms]
ECG (n = 50) 388.76 ± 31.48 411.86 ± 24.02
ECG exercise test (n = 40):
Rest 364 ± 32.27 412 ± 31.56
Peak exercise 255 ± 32.52
Recovery 346 ± 34.33 441 ± 35.05
Holter ECG (n = 35):
Mean 380.94 ± 30.7 432.77 ± 21.35
Maximal 435.68 ± 35.49 509.55 ± 35.47
Percentage of patients with certain QTc values:
> 440 ms 4.08%
> 460 ms 3.80%
> 470 ms 2.45%
> 480 ms 2.34%
> 500 ms 0.97%
ECG — electrocardiogram; SD — standard deviation
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Genotyping
Sixty blood samples for genetic testing were 
obtained. We have not found recessive mutations 
of KNCQ1 or KCNE1 typical for JL-N in any of the 
studied subjects. However, in 6 (10% of all geno-
typed) patients we have found other pathogenic mu-
tations in the KCNQ1 (1), KCNH2 (3), and SCN5A (1) 
genes and two mutations of unknown clinical 
significance, both in the SCN5A gene (Table 3). 
Three of these 6 patients had the R1047L muta-
tion in the KCNH2 gene, which is associated with 
the LQTS type 2 (LQT2). One of those 6 patients 
had coexistent R1047L mutation in the KCNH2 
gene with the R53Q mutation of unknown clinical 
significance in the SCN5A gene, which had been 
previously reported only once. Separately, 3 of 
those 6 patients were earlier diagnosed with epi-
lepsy. Finally, in 2 subjects of those 3 patients we 
have made the diagnosis of LQT2. These patients 
had been earlier incorectly diagnosed with epilepsy 
and were unsuccessfully treated with antiepileptic 
drugs. Both of these patients fulfilled first high-
risk criterion: they both had a history of loss of 
consciousness, previous diagnosis of epilepsy and 
a positive family history, and they had no significant 
QT prolongation: 396 ms and 352 ms, respectively. 
In other 3 patients, LQTS type 1, 2 and 3 have been 
diagnosed, respectively. Out of other 2 of those 
6 patients, 1 was found to have aP2005A mutation 
in the SCN5A gene, and another 1 had a R1047L 
mutation in the KCNH2 gene. They did not present 
any other symptoms of LQTS, despite significant 
QTc prolongation. In the last one of those 6 pa-
tients, who previously had been diagnosed with 
epilepsy and alpha-mannosidosis and who had 
QTc of 435 ms, a Q1033R mutation in exon 17 of 
the SCN5A gene was detected. This mutation has 
unknown clinical significance. The patient has not 
been diagnosed with LQTS.
Polymorphisms
Thirteen polymorphisms were identified in 
the study group (Table 4) including: 2 polymor-
phisms in the KCNQ1 gene (exons 13 and 16), 
6 polymorphisms in the KCNH2 gene (exons 6, 7, 
8, 11 and 12), 4 polymorphisms in the SCN5A gene 
(exons 2, 12, 17 and 28) and 1 polymorphism in 
the KCNE1 gene in exon 3. These allele frequen-
cies were similar in the hearing loss population 
and the general population. Twelve patients had 
a K897T polymorphism in the KCNH2 gene as-
sociated with the dysfunction of the potassium 
channel mediating IKr current. The Wilcoxon 
test was used to compare the QTc duration of the 
individuals with the found polymorphisms to the 
QTc duration of those without the polymorphisms. 
Only one (Y666Y) of the polymorphisms was as-
sociated with prolonged QTc reaching statistical 
significance (p = 0.008). Due to the small number 
(n = 7) of individuals carrying this polymorphism, 
these results have to be interpreted carefully and 
require further confirmation.
Table 3. Mutations found in high-risk patients with hearing loss.
Gender, age [years] High-risk criteria 
fulfilled
QTc [ms] Gene, exon Amino acid changes
Female, 15 Asymptomatic 480 KCNQ1 exon 13 R555H, pathogenic
Female, 13 Syncope
Epilepsy
Family history
396 KCNH2 exon 13 R1047L, pathogenic
Male, 19 Syncope
Epilepsy
Family history
352 KCNH2 exon 13 R1047L, pathogenic
SCN5A exon 2 R53Q, of unknown  
clinical significance,  
one previous report
Female, 21 Syncope
Epilepsy
Family history
435 SCN5A exon 17 Q1033R, of unknown  
clinical significance,  
not tested previously
Female, 39 Asymptomatic 467 SCN5A exon 28 P2005A, pathogenic
Male, 62 Asymptomatic 481 KCNH2 exon 13 R1047L, pathogenic
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Discussion
Our study population consisted of 1,080 sub-
jects with hearing loss, including 441 children 
younger than 14. Up to date, there is no data in the 
literature on QTc interval analysis within similar 
clinical context (hearing loss) and on such a large 
population. The largest study ever has been con-
ducted in California. It has researched 707 children 
younger than 6 years old [6]. There is a published 
study of ECG changes in 162 Polish children aged 
between 3 and 15 years with a hearing loss. In 
that cohort, QTc prolongation above the reference 
value was found in 16 patients (9.9% of the group), 
while high or intermediate probability of LQTS 
according to Schwartz’s criteria was identified 
in 27 (16.6%) children [7]. Furthermore, there 
has been a study published on 132 children with 
a hearing loss, among who 5 (3.8%) patients were 
diagnosed with JL-N syndrome [8]. On the other 
hand, in 350 Turkish children with congenital 
hearing loss, who were between the ages of 6 and 
19 years, LQTS (according to Schwartz criteria) 
was present in only 2 (0.57%) patients (girls aged 
14 and 15 years) [9]. In that Turkish study, the 
population of children was older than in our study. 
JL-N syndrome and LQTS can lead to sudden death 
at a very young age. According to Schwartz, the 
mortality reaches 20% within the 1st year after the 
syncope and 50% within the following 10 years. On 
the other hand, in the study of 276 Thai children 
with congenital sensorineural hearing loss the 
prevalence of the JL-N syndrome was reported at 
the 0.7% level [10].
We have not detected a single case of JL-N 
syndrome among 1,080 studied subjects who 
were affected by various degrees of hearing loss. 
It seems to be related to low incidence of this 
disease in the Central European population. Simi-
larly, the JL-N syndrome has not been detected in 
earlier mentioned study conducted in California 
[6]. Fraser et al. [11] estimated that the incidence 
of this syndrome in the pediatric population aged 
4 to 15 years in England, Wales and Ireland was 
between 1.6 to 6 in 1,000,000. So far, the highest 
incidence of JL-N syndrome of at least 1:200,000 
has been reported in Norway [12].
As noted, since we have diagnosed 5 patients 
with LQTS genotyping only 60 patients out of 
1,027 patients with hearing loss, one can make 
an estimation, that in a hearing loss population, 
LQTS can be observed at least with the incidence 
of around 1 in 205 patients, which is much more 
than previously reported by Schwartz et al. [13] — 
1 in 2,500–3,000 patients. It should be emphasized 
that the proposed strategy can be used not only for 
Table 4. Polymorphisms.
Gene Change* Frequency  
in control group
Frequency  
in patients with 
hearing loss
P Comments
KCNQ1 exon 13 S546S MAF(A) = 0.20 MAF(A) = 0.165 NS
KCNQ exon 16 Y662Y MAF(T) = 0.118 MAF(T) = 0.139 NS
KCNH2 exon 6 F513F MAF(A) = 0.368 MAF(A) = 0.34 NS
KCNH2 exon 6 I489I MAF(A) = 0.37 MAF(A) = 0.32 NS
KCNH2 exon 7 L564L MAF(A) = 0.39 MAF(A) = 0.29 NS
KCNH2 exon 8 Y652Y MAF(A)eu = 0.40 MAF(A) = 0.609 0.09 Unfavorable allele T 
KCNH2 exon 11 K897T MAF(G) = 0.129 MAF(G) = 0.196 NS Occurs in splicing region,  
regulatory impact
KCNE1 exon 3 S38G MAF(A) = 0.331 MAF(A) = 0.29 NS Serine (allele A) seems  
to be unfavorable 
SCN5A exon 2 A29A MAF(A) = 0.22 MAF(A) = 0.39 0.26 Unfavorable allele A 
SCN5A exon 12 H558R MAF(G) = 0.22 MAF(G) = 0.20 NS Benign change, regulatory impact 
SCN5A exon 17 E1061E MAF(T) = 0.08 MAF(T) = 0.07 NS Rare change
SCN5A exon 28 D1818D MAF(A) = 0.49 MAF(A) = 0.50 NS
KCNH2 exon 12 A572D MAF(A) = 0.001 2 cases Very rare change of unknown  
significance
*Amino acid abbreviations: S — serine, Y — tyrosine, F — phenylalanine, K — lysine etc.; MAF — minor allelic frequency based on 1000 Ge-
nomes, SIFT and PolyPhen
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the screening for the JL-N syndrome, but also, for 
the effective diagnosis of the LQTS.
The incidence of prolonged QTc in populations 
with a hearing loss was previously estimated at the 
level of approximately 4% [14, 15]. On the other 
hand, 2.5% of general neonatal population in Italy 
has been found to have QTc longer than 440 ms. 
In this study, the incidence of LQTS was reported 
at the level of 1:2,000–2,500 [13]. In our study, we 
have found higher incidence of QT prolongation in 
patients with hearing loss than previously reported 
in the general population, and this was particularly 
noticeable in children. This requires further con-
firmation in research. Identification of the genetic 
background of this phenomenon and assessment 
of the associated risk of dangerous arrhythmias 
are needed as well. Our results are compatible 
with those reported by Rokicki et al. [7] and many 
other authors: Chinagudi et al. [14] (2 of 50 [4%] 
children with congenital deafness had QTc longer 
than 450 ms), Niaz et al. [15] (4 of 104 [3.8%] of 
deaf children in Pakistan had QT longer than 440 ms), 
Srivastava et al. [16] (deaf girls compared to 
healthy girls, had significantly longer QTc at rest 
and after exercise), El Habbal and Mahoney [17] 
(congenital sensorineural hearing loss was associ-
ated with prolonged QT interval in 52 children aged 
8.35 years on average; mean QTc 417 ms ranging 
from 384 ms to 490 ms and Ilhan et al. [18] (QTc 
was significantly longer in 132 children with con-
genital hearing loss group vs. the control group; 
QTc measured 414 ± 42 ms on average, ranging 
between 319 ms and 572 ms, 5 patients had JL-N 
syndrome). It cannot be excluded that our method 
of measuring the QT interval is more accurate than 
manual measurement. If so, it may be required to 
modify reference values of the QTc intervals in 
the pediatric population. However, it should be 
emphasized that in our study, even in patients with 
abnormal QTc, the mean QTc interval was only 
slightly prolonged — still less than 490 ms. Also, 
no arrhythmia or syncope were observed in any 
of studied patients and only 3 asymptomatic indi-
viduals had pathogenic mutations. Furthermore, 
despite including 3 so-called large LQTS genes 
(KCNQ1, KCNH2, SCN5A) responsible for approxi-
mately 75% of all LQTS cases and the KCNE1 gene 
(a so-called small LQTS gene) [19], we identified 
only 3 mutations in 6 patients that are known to 
be responsible for the occurrence of LQTS. Addi-
tionally, only 3 (5%) patients with mutations had 
a significant increase in QTc on ECG screening. 
LQTS types 1 and 2 were found in 2 patients who 
had been unsuccessfully treated for incorrectly 
diagnosed epilepsy. As a result of genotyping per-
formed during our study we made the diagnosis 
of LQTS and started appropriate treatment with 
good result. This emphasizes the need to differ-
entiate epilepsy with LQTS. The role of the ECG, 
as an necessary investigation performed in any 
patient with syncope, along with genetic testing, 
which has a high diagnostic and prognostic value 
in LQTS, were both underlined [20, 21]. Our study 
has once again proven that genetic testing in sus-
pected LQTS should be used routinely in clinical 
practice [20]. Recently, the role of single nucleotide 
polymorphisms in KCNH2 and SCN5A genes has 
been reported as important factor associated with 
some cardiac diseases. The knowledge about single 
nucleotide polymorphisms (SNPs) in these genes 
and their associations with LQTS is limited and 
controversial, though some studies have revealed 
longer QT intervals in people with the K897T 
polymorphism in the KCNH2 gene [22, 23]. H558R 
polymorphism in the SCN5A gene was reported 
as possibly being able to modify expression of an 
arrhythmia causing mutations [24, 25]. We don’t 
know if SNPs in genes which encode sodium and 
potassium channels in cardiomyocytes  may also 
be associated in various hearing loss processes. In 
our study, the prevalence of particular SNPs was as 
in general population. Based on the findings of our 
study and on other reports we suspect the follow-
ing alleles to be associated with prolonged QTc in 
this population: K897T allele of the KCNH2 gene, 
H558R allele of the SCN5A gene, and A29A allele 
of the SCN5A gene, or any combination of these 
alleles, or a combination of these alleles with other 
genes. Further studies are necessary to prove this 
hypothesis or to explain the role these alleles play 
in mechanisms of hearing loss and the QTc prolon-
gation with the inherent risk of arrhythmia. Last 
but not least, we demonstrated an efficient use of 
telemedicine to transmit the large amount of ECG 
studies for a review to a cardiology center. Only 
selected patients who required further investiga-
tions needed to be referred to cardiology clinic. 
Similar telemedicine approach to ECG screening 
can be used in other populations.
Limitations of the study
The size of the studied population was too 
small to encounter such rare syndromes as JN-L 
is. We noticed that it may be sometimes difficult 
to measure QT accurately, especially when T wave 
is flattened. Additionally, in children RR intervals 
vary significantly from beat to beat and this raises 
the issue of under- or overestimation of QTc. 
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Relatively high incidence of QTc prolongation 
may be due to the method of measurement we 
used, which is possibly more accurate (enlarged 
and precise caliper) than manual measurement on 
ECG printed with the 25 mm/s paper speed. We 
should point out that none of cited references used 
this kind of precise technique of measurement. Not 
all patients from the high-risk group reported for, 
and some patients refused to participate in further 
cardiac studies.
Conclusions
Our study confirms that JL-N syndrome is 
extremely rare in the population of people with 
hearing loss. QT interval prolongation seems to be 
more frequent in patients (particularly in children) 
with hearing impairment than in the general popu-
lation; to explain this phenomenon further studies 
are required. In people with long QT interval and 
coexisting hearing loss, only genetic tests can 
confirm or rule out LQTS. A careful work up, in-
cluding genetic testing, should always precede the 
diagnosis of epilepsy with LQTS. To elucidate the 
role of particular alleles further studies are neces-
sary. It should be emphasized that ECG screening 
in a population of patients with hearing loss is 
important when additionally history of epilepsy, 
syncope or loss of consciousness is present.
The current technology enables ECG trans-
mission and is very efficient in screening of large 
populations of patients with no overt heart disease. 
It allows an expert assessment of the results of 
the studies and gives an opportunity to single out 
patients who might have various heart diseases, 
including these with dangerous arrhythmia.
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